Zordani Richard A. Jr.
CIK: 0001827180
Zordani Richard A. Jr.'s purchase track record
How the stock did after each of Zordani Richard A. Jr.'s open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since April 30, 2024
Stock higher 6 months later
33%
3 months: 67%
Median 6-month return
-27.4%
3 months: +17.8%
Beat the S&P 500
33%
median -43.2% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/24/2024 | GALT | $8K | +110.7% | +188.1% | +0.9% |
| 8/22/2024 | GALT | $8K | +17.8% | -36.4% | +9.8% |
| 4/30/2024 | GALT | $4K | -29.9% | -27.4% | +15.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| GALT | ▲ Buy | Open Market | 10,000 | $8K | 12/24/2024 | View on chart |
| GALT | ▲ Buy | Open Market | 1,759 | $4K | 8/23/2024 | View on chart |
| GALT | ▲ Buy | Open Market | 1,000 | $2K | 8/23/2024 | View on chart |
| GALT | ▲ Buy | Open Market | 741 | $2K | 8/22/2024 | View on chart |
| GALT | ▲ Buy | Open Market | 1,000 | $4K | 4/30/2024 | View on chart |
| GALT | ▲ Buy | Open Market | 5,000 | $13K | 7/28/2022 | View on chart |
| GALT | ▲ Buy | Open Market | 5,000 | $8K | 4/4/2022 | View on chart |
| GALT | ▲ Buy | Open Market | 5,000 | $10K | 1/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Galectin Clears Balance Sheet with $105M Debt Conversion
Galectin Therapeutics announced that a $105 million debt conversion has removed its outstanding debt, improving its balance sheet. The company still needs to secure a Phase 3 partnership to move its lead product forward. The move may reduce financial risk but the next milestone remains critical for the company's progress.
Galectin Clears Balance Sheet with $105M Debt Conversion. Galectin Therapeutics announced that a $105 million debt conversion has removed its outstanding debt, improving its balance sheet. The company still needs to secure a Phase 3 partnership to move its lead product forward. The move may reduce financial risk but the next milestone remains critical for the company's progress.